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Tumor-induced neurogenesis and immune evasion as targets
of innovative anti-cancer therapies
Rodolfo Daniel Cervantes-Villagrana 1, Damaris Albores-García2, Alberto Rafael Cervantes-Villagrana3 and Sara Judit García-Acevez4
Normal cells are hijacked by cancer cells forming together heterogeneous tumor masses immersed in aberrant communication
circuits that facilitate tumor growth and dissemination. Besides the well characterized angiogenic effect of some tumor-derived
factors; others, such as BDNF, recruit peripheral nerves and leukocytes. The neurogenic switch, activated by tumor-derived
neurotrophins and extracellular vesicles, attracts adjacent peripheral fibers (autonomic/sensorial) and neural progenitor cells.
Strikingly, tumor-associated nerve fibers can guide cancer cell dissemination. Moreover, IL-1β, CCL2, PGE2, among other chemotactic
factors, attract natural immunosuppressive cells, including T regulatory (Tregs), myeloid-derived suppressor cells (MDSCs), and M2
macrophages, to the tumor microenvironment. These leukocytes further exacerbate the aberrant communication circuit releasing
factors with neurogenic effect. Furthermore, cancer cells directly evade immune surveillance and the antitumoral actions of natural
killer cells by activating immunosuppressive mechanisms elicited by heterophilic complexes, joining cancer and immune cells,
formed by PD-L1/PD1 and CD80/CTLA-4 plasma membrane proteins. Altogether, nervous and immune cells, together with fibroblasts,
endothelial, and bone-marrow-derived cells, promote tumor growth and enhance the metastatic properties of cancer cells. Inspired
by the demonstrated, but restricted, power of anti-angiogenic and immune cell-based therapies, preclinical studies are focusing on
strategies aimed to inhibit tumor-induced neurogenesis. Here we discuss the potential of anti-neurogenesis and, considering the
interplay between nervous and immune systems, we also focus on anti-immunosuppression-based therapies. Small molecules,
antibodies and immune cells are being considered as therapeutic agents, aimed to prevent cancer cell communication with neurons
and leukocytes, targeting chemotactic and neurotransmitter signaling pathways linked to perineural invasion and metastasis.
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INTRODUCTION
Most cancers emerge from epithelial cells that suffer oncogenic
mutations in the coding sequence of proteins normally controlling
cell proliferation and survival.1 Driving genetic alterations that
cause cancer occur associated to multiple external factors,
including chemicals, toxins, radiation, and viral infection.2
Individual genetic background and conditions that affect homeo-
static circuits are recognized as predisposing factors.2 Tumor
growth and dissemination involves not only the proliferative and
invasive abilities of transformed cells but also the active
contribution of multiple cell lineages that turn bad under the
influence of oncogenic signals.3 In patients, the immune and
nervous systems are commonly coopted by tumors to favor
cancer progression.4–6 At metastatic stage, the deadliest phase of
cancer progression, cancer cells access the systemic circulation,
move and implant in distant organs where favorable substrates
allow cancer cell colonization and expansion.7 In the process,
reciprocal communication between immune and nervous systems
correlates with bad prognosis.8,9 The function of target organs is
compromised causing systemic failure that kills most patients with
metastatic cancers.7 Thus, understanding the cellular and mole-
cular basis of communication among multiple cells within tumoral
microenvironments emerges as the focus of basic and transla-
tional studies.
Uncontrolled cell division and altered patterns of gene
expression lead cell transition into mesenchymal phenotypes.10
Aberrant characteristics of malignant tissues are further exacer-
bated by non-transformed cells that join the stroma of growing
tumors in response to chemotactic signals.5 As they multiply in an
uncontrolled manner, malignant cells form small tumor masses
that require nutrients and oxygen to continue their expansion.11
Cancer cells at the center of millimetric tumors respond to local
hypoxic conditions activating signaling pathways that promote
synthesis and release of chemokines and growth factors the
transform the local environment.11 Immune, endothelial, and
neuronal, among other cell types, express receptors that respond
to these oncogenic cues.12–17 Following chemotactic factors, they
are recruited to primary tumors and metastatic niches becoming
part of complex communication circuits that exacerbate the
oncogenic process.5 Malignant cells invade surrounding tissues,
either displacing normal cells or hijacking them to integrate into
the stroma where their activities are redirected to benefit tumor
growth. These tumor infiltrated cells that constitute the stroma
include fibroblasts,4 endothelial cells, pericytes,12,13 bone marrow-
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derived cells (BMDC), tumor-associated monocytes and macro-
phages,14–16 endothelial progenitor cells (EPC),18–20 T regulators
(Treg),21 myeloid-derived suppressor cells (MDSCs),22 and neuro-
nal extensions;17 among other diverse components of the
neuroimmune axis and many other non-related lineages. Even-
tually, cancer cells exhibiting invasive and anchorage-free survival
properties disseminate and establish metastatic tumors.23,24 In the
process, newly formed capillaries not only maintain the supply of
oxygen and nutrients but also provide escape routes for
metastatic dissemination.7 Strikingly, nerve fibers also serve as
tracks guiding cancer cell migration.25
Targeting communication between tumor cells and the adjacent
vasculature is the basis of anti-tumor angiogenesis therapies.26
Effectiveness varies depending on tumor type and resistance is an
emerging problem.26 Various cell populations within the tumor
stroma might contribute to drug resistance and increased cancer
aggressiveness.27 Therefore, to achieve therapeutic efficacy,
translational studies are focusing on the immune system which,
instead of fighting transformed cells, is locally suppressed in the
tumor surroundings.28 Immunosuppressive mechanisms displayed
by cancer and stroma cells are being studied with the ultimate goal
to therapeutically rescue immune cells to fight cancer. More
recently, the nervous system, known to be compromised in cancer
patients, is being revealed as a participant of cancer progression.29
Particularly, tumor-induced neurogenesis joins angiogenesis and
immunosuppression as aberrant processes exacerbated within the
tumor microenvironment.
Cell communication networks in cancer
Oncogenic communication networks established within the tumor
microenvironment also exhibit systemic effects via tumor-derived
mediators leaked to the circulation (Fig. 1). Invariably, some normal
adjacent cells (as fibroblasts and endothelial,4,12,13,30 as well as
distant cells (as bone marrow-derived cells31,32 respond as tumor
subordinates, facilitating neoplastic progression. Under the influ-
ence of cancer cells, these normal (non-transformed) cells join the
tumor stroma where, responding to an aberrant microenviron-
ment, express a repertoire of genes including those coding for
soluble chemotactic factors.33 Besides establishing reciprocal
communication with cancer cells, cells within the tumor stroma
secrete factors that augment the repertoire of chemoattractants
that recruit additional cell populations that join primary tumors
and contribute to establish metastatic niches.17 Cancer progression
is further exacerbated under the influence of cytokines, neuro-
transmitters, and neuromodulators affecting different components
of the neuroimmune axis.17 Conclusive evidence points to a pro-
tumoral role of certain relevant subsets of immune cell popula-
tions. Regarding the nervous system in the context of cancer
progression, recent reports support the idea that nervous cells and
soluble factors inherent to their communication also contribute to
cancer progression.6 Therefore, translational research focuses on
disrupting cellular communication as a strategy to fight tumor
growth and dissemination. In the next sections, we discuss how
tumor cells communicate with the immune (Section “Evasion of
the immune response: aberrant communication between cancer
and immune cells”) and nervous system (Sections “Reciprocal
communication between cancer cells and the nervous system
promotes tumor progression” and “Classical central nervous
system neurotransmitters (dopamine, glutamate, and GABA)
impact cancer progression”). In this context, we describe potential
therapeutic targets as coadjuvants of conventional therapies.
Cancer cells evade the immune system by recruiting and
controlling immune cells. Cytotoxic T cells and natural killer cells
(NK) follow tumor-derived chemotactic factors to be incorporated
into growing tumors.34 Although expected to induce apoptosis of
transformed cells, cytotoxic T cells, and NK cells are instead
suppressed within the tumor microenvironment either by direct
contact with cancer cells or under the influence of inhibitory
factors.34 Furthermore, infiltrated Treg cells and macrophages
contribute to these immunosuppressive effects on T cells and
NKs.35 M2 macrophages also help in the promotion of tumor
angiogenesis and proliferation.36
Communication between tumors and the nervous system is
reciprocal. Cancer patients suffer neuropathic pain.37 The under-
lying neuro-oncogenic processes include pressure on fibers as
tumor volume increases,38 secretion of stimulatory factors on
peripheral fibers with depolarizing effects,39,40 axon demyelina-
tion,41 and pathological neural plasticity induced by tumor-
derived factors.42–44 Moreover, cancer treatments, including
chemotherapy (as platinum analogs, taxanes, and vinca alkaloids)
and radiation, affect the nervous system causing pain. Therefore,
cancer treatments commonly include painkillers, some of them
extremely potent and addictive.38,45 Besides being a victim of
cancer growth and dissemination, the nervous system is engaged
by cancer cells and tumor infiltrated leukocytes to promote tumor
growth and dissemination (as described in Section “Reciprocal
communication between cancer cells and the nervous system
promotes tumor progression”). For instance, a rat model of breast
and bone cancer in which persistent pain coincided with tumor
growth, served to reveal a mechanistic link between pain and
tumor growth.46 These studies demonstrated antitumoral effects
of drugs with anesthetic (bupivacaine) and analgesic (morphine)
properties.46 These findings were interpreted as indicative of a
pro-tumoral role of active peripheral fibers involved in neuro-
pathic pain, which putatively release pro-tumoral factors. Thus, the
vicious tumor-promoting circuit is initiated by cancer cells that
release axonogenic neurotrophic factors, directly communicating
the tumor stroma with the peripheral nervous system (PNS). As a
consequence of tumor innervation, neuromediators released by
tumor-associated fibers promote cancer cell proliferation and
migration.47 In addition, sympathetic and parasympathetic fibers
release noradrenaline and acetylcholine (ACh), among other
neuromodulators, within the tumor and lymphoid organs to
decrease anti-tumor immunological response.48
A variety of cell lineages within growing tumors are integrated
into aberrant communication networks based on multiple
chemotactic agonists secreted by cancer and stroma cells.30,49
Major chemoattractants include chemokine (C–C motif) ligand 2
(CCL2) and stromal-derived factor 1 (SDF-1/CXCL12) that recruit
bone marrow-derived cells and M2 macrophages, upon the
actions of CCR2 and CXCR4 receptors, respectively.49 In addition,
prostaglandin E2 (PGE2) stimulates immunosuppressor MDSC cells
which, as an evasion mechanism within the tumor microenviron-
ment, arrest immune cell maturation, sustaining local immuno-
suppression.22 Thus, G protein-coupled receptors (GPCRs), the
targets of these agonists, and their intracellular signaling hard-
ware, play a prominent role in cancer. Moreover, GPCRs and their
signaling transducers have been revealed as driving oncogenes
themselves. Examples include activating mutations in GPCRs (e.g.
CysLT2R-L129Q in uveal melanoma
50) and heterotrimeric G
proteins (e.g. Gαq/11-Q209L51 in uveal melanoma, Gαs-R201C in
pancreatic cancer,52 and Gβ1-K57E/N/T, Gβ1-I80N/T or Gβ1-K89E/T
in leukemias53), as well as changes in their expression and
signaling properties.12,13,54–56 However, although targeted anti-
cancer therapeutic strategies are commonly used towards tyrosine
kinase-linked receptors (using kinase inhibitors and humanized
antibodies together with cytotoxic/cytostatic agents), coadjutant
therapy targeting GPCRs has not been fully exploited, as it would
be expected given their prominent role within the tumor
microenvironment.
Emergent relevance of extracellular vesicles in oncogenic cell
communication
Cell–cell communication through extracellular vesicles (EVs) as
exosomes and microvesicles and its role in cancer progression has
been amply discussed in previous reviews.57,58 Leukocyte activity
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in favor of tumor growth might be mediated by signaling
elements incorporated by fusion of EVs. Given the diversity of
proteins and other molecules transferred by this mechanism, the
range of possibilities to explore therapeutic alternatives is
enormous. Hypothetically, all communication networks could be
modulated by EVs. For instance, tumor cells release
MET+-exosomes that target endothelial progenitor cells. When
fused to target membranes, tumor-derived exosomes enable
target cells to respond to hepatocyte growth factor (HGF). In this
way, tumor-derived exosomes actively contribute to tumor
vascularization and growth.31
Targeting the exosome communication system has been
postulated as a potential therapeutic strategy to fight metastasis.
As cancer progression markers, exosomes with specific integrins
predict metastatic organotropism.59 Tumor-derived exosomes
contain integrins that prepare organ-specific sites where meta-
static niches are established.59 These exosomes are uptaken by
targeted resident cells like fibroblasts, macrophages, epithelial,
and endothelial cells where they activate Src signaling and pro-
inflammatory S100 gene expression.59 In murine breast cancer
models, specific integrins, transferred by exosomes, determine the
target organs where metastatic niches are prepared. The proposed
model postulates that cancer cells release exosomes having α6β4
and α6β1 integrins that are incorporated at lungs, preparing the
ground to receive metastatic cancer cells. In the case of liver
metastasis, an equivalent effect has been experimentally attrib-
uted to exosomal αvβ5 integrins.
59 Experiments using exosomes
collected from knockdown cancer cells, having reduced expres-
sion of targeted integrins, resulted on decreased exosome uptake
at the target organ and reduced metastasis.59 Given their tropism
for metastatic niches, engineered extracellular vesicles might
serve as drug delivery systems. Microbubbles have been designed
as microcapsules containing chemotherapeutic drugs, either
transported inside or at the microbubble surface.60 Doxorubicin,
paclitaxel, docetaxel, and carmustine are amongst the drugs
tested. Also, ultrasound-induced destruction of microbubbles has
been introduced to further control drug delivery. Drug-loaded
microbubbles, sensitive to ultrasound-controlled release, can
deliver drugs at primary tumors and metastatic sites. This
noninvasive tool, inspired by the mechanisms of exosomal
communication, will likely increase the power of targeted
therapies.61
EVASION OF THE IMMUNE RESPONSE: ABERRANT
COMMUNICATION BETWEEN CANCER AND IMMUNE CELLS
The immune system dictates the fate of carcinogenic processes.
Normally, CD8+ T cells62 and NK cells63 are endogenous vigilantes
that destroy transformed cells using granzyme and perforin as
weapons. During immunosurveillance, NK and T cells expressing
Fig. 1 Oncogenic communication networks link tumor cells with the neuro-immune-vascular systems. Representative communication
networks among tumor-associated stroma cells including fibroblasts, immune cells, vascular cells, and neuron fibers. Cell communication is
either direct or mediated by cytokines, chemokines, growth factors, and fatty-acid-derived agonists. Tumor cells are positively regulated by
the immune system and exhibit mechanisms to evade the antitumoral immune response. Additional communication networks, relevant for
tumor vascularization, involve the contribution of fibroblasts, endothelial cells, pericytes and bone-marrow-derived cells including endothelial
progenitor cells and Tie2-expressing monocyte/macrophages. Several populations of BMDC are recruited to the tumor microenvironment and
niches, where they can differentiate to pro-tumor population as EPC, MDSCs, and macrophage-like cells, among others. Tumor-derived
angiogenic factors promote migration and proliferation of adjacent vascular cells and BMDCs to create new vessels, growing with tumors.
Central and peripheral nervous systems promote tumor growth, neurons release neurotransmitters with proliferative and migration/invasion
properties on stroma and cancer cells. Peripheral nervous fibers (autonomic and sensorial) are attracted by the tumor microenvironment via
axonogenesis. Tumor-derived factors recruit neural progenitor cells (NPC) to promote intratumor neurogenesis. The direction/effect arrows
indicate potential targets that might be modulated by specific antagonists or agonists. Intratumor sympathetic fibers are associated in early
phases of cancer triggering an angiogenic switch via adrenergic signaling. In later phases, parasympathetic fibers contribute to stimulating
cancer cells to invasion and metastasis. BMDC bone-marrow-derived cell
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FasL induce apoptosis of cancer cells having functional Fas
receptors (a death receptor).64–66 However, cancer cells with
altered Fas receptors evade the immune response.64,67 Besides
these survival mechanisms, cancer cells can activate local
immunological tolerance by overexpressing certain ligands, such
as programmed cell death-ligand 1 (PD-L1), that keeps NK and
T cells under their control.68
Mechanistically, survival signaling in T cells is repressed by
intracellular phosphatases activated by PD-1 upon interaction with
PD-L1 (and also PD-L2) expressed on the surface of malignant
cells.68 Furthermore, immunosuppressive cells are recruited by
cancer cells to reinforce their anti-immune mechanisms, thus
contributing to tumor growth and expansion. Cell populations
with immunosuppressive effects include regulatory T lympho-
cytes,69 MDSCs70 and M2 macrophages,5 as shown in Fig. 2.
The immune response is modulated by fatty acid-derived
factors, including resolvins, pronectins, lipoxins, and endocannabi-
noids, among others, released by cells involved in inflammation
resolution mechanisms;71 In addition, acetylcholine, known to be
involved in the cholinergic reflex, activates α7 nicotinic receptor in
immune cells, triggering immunosuppressive JAK2/STAT signal-
ing.71 Endocannabinoids, known as neuromodulators within the
central nervous system (CNS), control secretory properties of
immune cells. Therefore, they regulate the systemic availability of
interleukins.72 Endocannabinoids such as anandamide (AEA) and 2-
acylglycerol (2-AG) directly target leukocytes and also exert their
neurological effects by suppressing substance P (SP) and calcitonin
gene-related peptide (CGRP) of C fibers.72 In fact, Gi-coupled
receptors expressed in the sensorial afferents potentially inhibit
secretory activities of cells within the tumor microenvironment.73
Fig. 2 Oncogenic communication between cancer cells and tumor-associated stroma cells: immunosuppressive and proangiogenic switches.
Tumor cells secrete a wide variety of factors that promote the recruitment of different cell types. The immune response evasion occurs by
cell–cell interaction through transmembrane proteins as PD-L1/PD-1 and B7/CTLA-4, inhibiting cytotoxic activity. Tumor-derived factors
recruit immunosuppressive cells (M2 macrophages, MDSCs, and Tregs) and promote the transition from anti-tumor to pro-tumor cells
including M1 to M2 macrophages. Autonomic and sensorial fibers release neurotransmitters and neuropeptides that regulate the immune
response. Parasympathetic fibers release acetylcholine, thus inhibiting immune response via nicotinic receptors, while sensorial fibers release
substance P and CGRP to activate mast cells and blood vessels. To provide nutrients to the tumor, pro-angiogenic cell communication is
required. Release of factors as VEGF, ANG2, CXCL12, and S1P by tumor cells, leukocytes (macrophages and mast cells), and tumor-associated
fibroblasts provides an enriched microenvironment proper for tumor vascularization. The insert shows the immunosuppressor switch where
in early phase of tumor development cells with anti-tumor functions are recruited, including M1 macrophages and cytotoxic T lymphocyte
(CTL); yet they are progressively transformed and attract immunosuppressor and pro-tumor cells. In late phases of cancer these pro-tumor
populations are enriched, correlating with high aggressiveness and low survival
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PD-L1/PD-1 and CD80/CTLA-4 protein complexes at
immunological synapses trigger evasion mechanisms controlled
by cancer cells
Protein–protein interactions established by direct contacts
between cancer and immune cells create communication path-
ways that allow cancer cells to evade the immune response.
Cancer cells hijack the regular mechanisms by which the immune
system limits cytotoxic T cell activity in inflammation, autoimmune
response74,75 and tolerance,76 which is normally mediated by
programmed cell death protein 1 (PD-1; also known as CD279).76
Expression of this integral membrane protein is inducible in T cells,
B cells and activated peripheral monocytes. PD-1 receptor is
activated by two ligands with different expression patterns: PD-1
ligand (PD-L1; B7-H1) and PD-L2 (B7-DC).76 Both of them decrease
interleukin 2 (IL-2) and interferon γ (IFN-γ) production, reducing T
cell proliferation and cytotoxic effects.76 The PD-L/PD-1 system
normally regulates the immune response. In the process of
activating the immune response, PD-L1 is constitutively expressed
in T cells, B cells, dendritic cells and macrophages, and up-
regulated on stimulated T cells77; but also in parenchymal cells
including, endothelial cells and islets of Langerhans.78 In contrast,
PD-L2 is induced in dendritic cells, macrophages77,79 and active
T cells.80 By activating intracellular phosphatases (as SHP2), this
system suppresses the signaling of immune-response receptors as
T-cell receptor (TCR).71
PD-1 cytoplasmic tail contains two phosphorylation-dependent
motifs, an ITIM (Immunoreceptor Tyrosine-based Inhibition Motif)
and an ITSM (Immunoreceptor Tyrosine-based Switch Motif),
which are characteristic of the superfamily of inhibitory receptors
that promote inflammation resolution.71 The suppressor effect of
PD-1 was demonstrated with a chimeric protein composed by the
extracellular domain of murine CD28 (co-receptor of TCR) fused to
human PD-1 cytoplasmic tail. This chimeric receptor inhibited T
cell proliferation and cytokine production.81 PD-1 ITSM motif
serves as docking site for SHP-1 (Src-homology region 2 domain
containing phosphatase-1) and SHP-2 phosphatases.81 A mutation
at this site abrogates PD-1 suppressive effect.81 However, whether
cancer cells activate this immunosuppressive signaling pathway in
immune cells remains to be fully clarified. Overexpression of PD-L1
in cancer cells correlates with drug resistance and poor
prognosis.82–90 Therefore, anti-PD-1 immunotherapy has gained
enormous clinical relevance and its suitability in different
conditions is the focus of hundreds of clinical trials (https://
clinicaltrials.gov/).
Immunotherapy with anti-PD-1 antibodies increases the infiltra-
tion of CD8+ cytotoxic T cells into soft tissue sarcomas,91
melanoma,87 and murine renal cancer.92 Conventional chemother-
apy and therapeutic protein kinase inhibitors are expected to
improve their efficacy when combined with anti-PD-1 antibo-
dies.93 Encouraging results have been reported in preclinical
studies of ovarian cancer,94 and T-cell non-Hodgkin lymphoma.95
Also, anti-PD-1 monoclonal immunotherapy enhances the effect
of a vaccine against hepatocellular carcinoma (GPC3-derived
peptide vaccine, phase II) in patients.96 In certain conditions, anti-
PD-1 antibodies have demonstrated to be effective even in cases
of drug resistance to cytotoxic chemotherapy. For instance,
pembrolizumab, a monoclonal anti-PD-1 antibody, showed anti-
tumor effect in a patient with a solitary fibrous tumor of pleura
resistant to chemotherapy. The therapeutic antibody was well
tolerated and did not generate significant adverse effects over the
therapeutic cycle.97 Overall, the proof of concept regarding the
therapeutic use of anti-PD-1 monoclonal antibody is well
established. It is expected to be effective in cancers where
evasion of the immune system plays a fundamental role in tumor
progression.
A second immunomodulatory system hijacked by cancer cells is
the one composed by CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4)
receptor, known to be exclusively inducible expressed in
T lymphocytes, and constitutively expressed in regulatory
T cells (Tregs).98 Normally, this system attenuates effector T
cells (CD4+CD25-) and enhances regulatory T cells
(CD4+CD25+).99–101 It is physiologically activated by antigen-
presenting cells expressing CD80 (also known as B7.1) and CD86
(also known as B7.2), known CTLA-4-ligands. Immunosuppres-
sive activity of certain cancer cells is gained by expression of
CD80 and CD86.102,103 CTLA-4 and CD28 (co-receptor of TCR)
recognize the same ligands. CTLA-4 is induced after TCR
activation and competes with CD28 for ligands to inhibit TCR
via phosphatases as SHP-2 and PP2A.104–106 The interaction of
CTLA-4 with phosphatase SHP2 requires a tyrosine-
phosphorylated Tyr-Val-Lys-Met (YVKM) motif in the cytoplas-
mic tail of CTLA-4 to regulate the TCR activity; in fact, T cells, in
the absence of CTLA-4 have an hyperactive TCR signaling (Fyn,
Lck, ZAP-70) leading to pro-inflammatory functions.107 While
the catalytic subunit of the serine/threonine phosphatase PP2A
also interacts with the YVKM motif of CTLA-4.105 The phospha-
tase PP2A mediates CTLA-4 signaling to inhibit the activation of
T cells;108 in fact, PP2A is a target for immunotherapy, and the
inhibition of the phosphatase activity increases the cytotoxicity
of intratumor lymphocytes.109 For PD1 and CTLA-4 receptor, it is
necessary to have in vivo evidence showing how the
immunosuppressive effects in several tumor microenviron-
ments are mediated by the direct activation of phosphatases.
Partial blockade of CTLA-4 shows therapeutic potential as it
increases the antineoplastic effect of non-selective cytotoxic
substances contributing to tumor regression in experimental
cancer models, whereas non-immunogenic tumors are resistant.
However, excessive blockade of CTLA-4 with therapeutic purposes
has been controversial as it can cause an autoimmune disorder
due to a lymphoproliferative effect.110 In clinical settings, anti-
CTLA-4 monoclonal antibodies (ipilimumab and tremelimumab)
are particularly effective in patients with melanoma.111,112 Also,
promising results have been obtained in the treatment of patients
with refractory head and neck squamous cell carcinoma,113
metastatic sarcoma,114 metastatic colorectal cancer,115 small-cell
lung cancer,116 non-small-cells lung cancer,117,118 metastatic renal
cell carcinoma,119 and malignant mesothelioma.120–122 As com-
bined therapy, anti-CTLA-4 improves the antitumoral effect of
conventional cytotoxic substances. As mentioned before, blocking
the CTLA-4 receptor increases CD4+ T cells activities therefore
stimulating effector cells.
Regulatory T cells (Tregs) promote the tumor growth via inhibitory
cytokines
The antitumor effect of anti-CTLA-4 monoclonal antibodies is
based on their ability to deplete CD4+/FOXP3+ T regulatory cell
population.123 T regulatory cells need CTLA-4 for suppressive
function, in fact, CTLA-4-deficient Tregs increases immunity
against tumors in mice.100 Similarly, anti-PD-1 monoclonal
antibodies interfere with the ability of these cells to communicate
with antigen-presenting cells.124 Regularly, Tregs maintain
immune tolerance. They are an immunosuppressive population
of CD4+/CD25+ T cells, identified in 1995 by Sakaguchi et al.35
Further characterization of this cell population led to the
identification of FOXP3, as a marker of regulatory T cells.125,126
FOXP3 directly suppresses IL-2 gene expression and increases
CTLA-4 and CD25 expression.127 In addition, via secretion of
inhibitory cytokines as IL-10, IL-35 (interleukin-10/-35), and TGFβ
(Transforming Growth Factor-β), T regulatory cells inhibit gran-
zyme and perforin expression in antigen-presenting cells and
degrade ATP, causing energy deficiency.128 Several preclinical
studies have reported that Treg cells play a fundamental role in
tumor immunity, since depletion of this T cell population, using
monoclonal antibodies against CD25+, prevents tumor growth.129
In clinical studies, increased presence of Treg cells is indicative of
bad prognosis in ovarian cancer.130 However, in the case of
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colorectal cancer, controversial findings have been reported
regarding whether increase of Tregs infiltrated into tumors
improves or worsens the prognosis.131 These data suggest that
further sub-classification of Tregs is required to explain differences
in the outcome of various types of cancers. Additional markers
might increase the effectiveness of precision immunotherapies.
Given the success of anti-CD25 antibodies preventing tumor
growth in preclinical cancer models, current clinical trials are
addressing the blockade of Treg CD25+ receptor with daclizumab,
a humanized monoclonal antibody. This antibody was tested in
patients with metastatic melanoma together with vaccination of
dendritic cells. As a result, Treg cells in peripheral blood were
depleted, but antitumor effector T response was not achieved.132
In contrast, daclizumab followed by vaccination potentiated the
antitumor response in breast cancer patients.133 Since Treg cells
produce TGFβ, a cytokine whose signaling promotes cancer
progression and metastasis of several types of cancers, additional
therapeutic efforts are oriented to target TGFβ receptors.
TGFβ-dependent effects are linked to tumor-induced angiogen-
esis and direct immunosuppressive effects mediated by a
decrease on the innate and adaptive antitumor immune
response.134 Preclinical studies on the therapeutic potential of
galunisertib (LY2157299), an inhibitor of TGFβ serine/threonine
kinase type 1 receptor (TGFβ-RI), have shown anti-tumor effects in
neuroblastoma and hepatocellular carcinoma, showing an
increase on natural killer cells;135 and modulating the expression
of CD44+,136 respectively. Clinical trials are underway to explore
the use of this kinase inhibitor in recurrent glioblastoma,137 and
advanced pancreatic cancer,138 among others.
MDSCs and macrophages contribute to evade anti-tumor
responses
Immunosuppressive cell populations contribute to antitumor
evasion. Myeloid-derived suppressor cells (MDSCs) were first
described in 1987 in a mouse lung cancer model. In lung tumors,
they were recognized as frequent infiltrating immature myeloid
cells and their immunosuppressive functions were postulated.
However, these initial, visionary experiments, were not further
pursued.139 It is now established that MDSCs are myeloid cells
similar in their origin to macrophages, granulocytes, and dendritic
cells.140 This heterogeneous cell population emerge under patho-
logical conditions such as cancer, inflammatory diseases, auto-
immune diseases and chronic viral infections, conditions that
interrupt the maturation process normally occurring in this cell
population.141,142 MDSCs, identified in human spleen, are classified
in two main subpopulations: granulocytic- and monocytic-MDSCs.
These cells express several plasma membrane markers (Lin−,
CD11b+, CD33+, HLA-DR−); additionally, CD14+, CD15+ charac-
terizes granulocytic MDSCs, whereas monocytic MDSCs are CD14+,
CD15−.143 Immunosuppressive effects of MDSC are mediated by
three major mechanisms: (1) Reactive oxygen species (ROS) that
block macrophages and dendritic cell differentiation;144,145 (2)
inducible nitric oxide synthase (iNOS) associated with decreased T
cell expansion and proliferation capabilities;146 and (3) Arginase-1
(Arg1) that diminish T-cell metabolism and promotes TCR
nitrosylation, ultimately leading to apoptosis.147 Other mechanisms
of immune regulation by MDSCs have been described, they include
alterations in antigen presentation, T cell signaling, immunosup-
pressive and pro-apoptotic factor production, induction of inhibi-
tory signaling cascades and recruitment of regulatory T cells.148 In
response to tumor antigens presented as peptides on the surface of
MDSCs, they inhibit IFN-γ production by CD8+ T cells.149 In vivo,
MDSCs induce antigen specific tolerance in T lymphocytes.150
Clinical studies revealed that increased levels of MDSC correlate
with poor prognosis in cancer patients.151 After exacerbated
responses, these cells contribute to restore homeostasis.
Therapeutic reduction of MDSCs population would diminish
immunological antitumor tolerance. Conventional chemotherapy
contributes to this goal. For instance, in gastric cancer models,
cytotoxic chemotherapy with ipirubicin and paclitaxel decrease
MDSCs population as a consequence of anti-proliferative and pro-
apoptotic effects in which the MAPK and NFκB signaling pathways
are involved.152 Also, acute lymphocytic leukemia patients treated
with chemotherapeutic molecules have less suppressor cells,
which contributes to a better prognosis.153 Breast cancer patients
expressing IL-17, and a STAT3 activated pathway, have less tumor-
infiltrated MDSCs,154 raising possibilities to target IL-17 as a
therapeutic alternative. Altogether, these studies highlight the
importance of studying immunosuppressive cell populations as
targets of therapeutic alternatives against cancer. Prostaglandin E2
(PGE2) induces the differentiation of MDSC cells via E-prostanoid
(EP) receptors. Differentiation is blocked by antagonists of
prostaglandin receptors: EP4 (AH23848), EP1/EP2 (AH6809); and
cyclooxygenase-2 inhibitor (COX2 inhibitor SC58236). In a
preclinical tumor model using 4T1 mammary carcinoma cells,
EP2-deficient mice showed decreased tumor growth and MDSC
infiltration; similarly, wild-type mice treated with COX2 inhibitor
showed reduced primary tumor growth and delayed MDSC
accumulation.22 In cancer therapy, EP receptor antagonists and
COX2 inhibitors may attenuate the accumulation of MDSCs and
their contribution in tumor growth.
Tumor-associated macrophages (TAMs), as Tregs and MDSCs,
are infiltrated within the microenvironment of most solid
tumors.155 TAMs express PD-L1 which, as previously described,
can directly decrease T cell activation. Normally, macrophages
produce matrix metalloproteinases (MMPs) involved in physiolo-
gical angiogenesis and tissue repair.156 In the case of tumor-
associated macrophages, those with M1 phenotype exhibit a
tumor suppressor role,157 whereas M2 macrophages have
immunosuppressive effects propitiating tumor growth and
metastasis. Within the tumor microenvironment, acquisition of
M2 phenotype is promoted in response to IL-10 and IL-4
cytokines, in addition to some growth factors such as vascular
endothelial growth factor A (VEGF-A)158,159 and catecholamines
(noradrenaline and adrenaline) released by tumor-associated
sympathetic fibers and adrenal glands.160 As with other immuno-
suppressive cell populations, reducing M2 macrophages likely
improves patient prognosis, as it has been recently shown in skin
cancer patients. Clinical trials testing emactuzumab, which targets
colony-stimulating factor receptor 1 (CSF-1R) decreasing the M2
macrophage population, have reportedly improved prognosis of
skin cancers patients, like those with melanoma.161,162
Macrophages are heterogeneous and can be functionally
polarized in pro-inflammatory M1 macrophages (classical activa-
tion by IFNs, Toll-like receptor) or anti-inflammatory M2 macro-
phages (alternative activation by IL-4/IL-13). M1 macrophages are
anti-tumor, while M2 macrophages are pro-angiogenic and
immune suppressors.163–165 M1 and M2 differ in the expression
of receptors, cytokine and chemokine production and effector
function.166 Patients with high infiltration of M1 macrophages had
better survival versus low infiltration; in contrast, high infiltration
of M2 macrophages had worse overall survival versus low
infiltration.165
Anti-tumor M1 macrophages are recruited in early phases to
tumor development, but are progressively differentiated to M2
with pro-tumor effect.167,168 Reduced hypoxia in early phases of
tumor progression allows the accumulation of M1 macrophages,
increasing antigen presentation and promoting antitumor cyto-
toxicity by T cells. As tumor hypoxia increases, cytokine
production for the anti-tumor response becomes deficient and
results in tumoricidal decline and progressively macrophages
acquire pro-tumor M2 functions driven by the tumor microenvir-
onment167,169 including IL-4 and IL-10 159. The overexpression of
the p50 subunit of NFκB in macrophages promotes the re-
polarization of M1 to M2, gradually atrophying the efficient anti-
tumor response and switching to pro-tumor functions by
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accumulation of p50 homodimers. In p50 deficient mice or with
restricted deficiency in bone marrow cell, it retards the growth of
melanoma (B16) and fibrosarcoma (MN/MCA1) tumors.168 The
evidence suggests that there is an immune-suppressor switch that
promotes the change of populations of anti-tumor immune cells,
such as M1, to populations of immunosuppressive cells such as M2
macrophages.167 The polarization of macrophages could be a
therapeutic target, establishing immunotherapies for the accu-
mulation of M1 macrophages with tumoricidal functions by
recruiting and preventing their desensitization and switching to
M2. It is necessary to clarify the ways of differentiation to M2 for a
more rational therapy.
Tumors recruit cells of the immune system. Tumor-associated
monocytes/macrophages are recruited into the tumor microenvir-
onment by chemokines such as SDF-1 and CCL2. In these settings,
activation of CXCR4 and CCR2 receptors promote Gi-dependent
cell migration.49 Interestingly, the intratumor differentiation of
monocyte to macrophage requires CCR2 downregulation to retain
the cell in the tumor.166 In cancer patients, populations of Tie2-
expressing monocytes/macrophages (TEMs) colonize tumors.
These cells migrate in response to angiopoietin-2 (Ang2), a Tie2
ligand, released from activated endothelial cells during angiogen-
esis.15 Reciprocal communication between tumor cells and TEMs
contributes to tumor progression. For instance, Tie2+/CD11b+/
CD45+ bone-marrow-derived cells promote tumor growth in lung
carcinoma mice models. BMDCs secrete factors that stimulate
cancer cell migration via Gi-coupled receptors signaling via
Gi→Gβγ. Chemotactic GPCRs and their Gβγ-dependent signaling
effectors are essential to promote cell migration within the tumor
microenvironment and at a systemic level to recruit normal
somatic cells to growing tumors.16,170
Semaphorins are a family of membrane-associated or secreted
glycoproteins, initially involved in axonal guidance, and relevant
to cancer progression by modulating cell migration of leukocytes,
neurons, and endothelial cells.171 In tumor-associated macro-
phages, semaphorin 4D (Sema4D), induces tumor angiogenesis
and vessel maturation by binding to the plexin B1 receptor on
endothelial cells, and the effect is blocked by plexin B1 antibodies,
and by the c-Met inhibitor (PHA-665752). In fact, knocking out of
Sema4D prevents tumor growth and metastasis in a breast cancer
murine model (TSA cells).172
Catecholamines activate the immunosuppressor switch in the
tumor microenvironment (TME) of lung cancer accumulating M2-
polarized macrophages and MDSCs while decreasing antitumoral
dendritic cells (DC).160 Tumor-associated M2 macrophages
synthesize and release VEGF, promoting angiogenesis, which is
induced by adrenergic signaling in macrophages.160 Moreover, re-
polarization of M1 to M2 macrophages by tumor catecholamines
leads to the synthesis and release of IL-10, an immunosuppressive
cytokine for TME.160 The inhibition of adrenergic signaling
increases the antitumor immune response via the impact on
multiple leukocytes.
Neuronal regulation by tumor-associated leukocytes
The role of the nervous system in regulating the immune response
in infection and inflammatory processes is known.173 In the
opposite direction, it has been described that mediators released
from leukocyte populations can modulate the activity and
prolongation of the adjacent nerve fibers and infiltrate to the
tumor.174,175 Inflammatory mediators lead to the activation of
peripheral sensory fibers that, in addition to promoting pain, lead
to the release of substance P, a neuropeptide that promotes
tumor growth.46,176 Vasodilation of peri- and intratumor vessels, as
well as increased vascular permeability by tumor-derived vasoac-
tive factors contribute to the extravasation of leukocytes to access
the tumor and the intravasation of metastatic cells.177
Inflammation processes induce the accumulation of leukocytes
and the release of pain-associated mediators, promoting neuronal
plasticity and peripheral innervation.178 Pain research, including
cancer pain, highlight the contribution of macrophages-derived
neurotrophins and other non-neuronal cells, in the stimulation of
nociceptors and damaged nerves, enhancing pain and generating
aberrant neuromas that spontaneously depolarize, contributing to
neuropathic pain.178,179 M2 macrophages are functionally recruited
and aid in nerve repair and possibly tumor innervation, in contrast
M1 functions to destroy the injured nerve.180 Macrophages
regenerate the injured nerve through secretion of VEGF that
guides the growth of new blood vessels, used by Schwann cells to
migrate and guide the nerve growth,174 a mechanism that can be
used in tumor angiogenesis and axonogenesis. In addition,
Sema4D can induce neurite outgrowth,181,171 and this semaphorin
is mainly expressed in tumor-associated macrophages promoting
tumor angiogenesis,172 but possibly also tumor innervation.
Neurotrophins, as nerve growth factor (NGF), when released by
macrophages, mast cells, and other leukocytes could be promot-
ing to axonogenic switch for tumor innervation, as occurs in
inflammatory pain178 and neurogenesis by recruiting brain-
derived neural precursors for cancer progression (Section “Tumor
neurogenesis: CNS-derived neural progenitor cells infiltrated in
tumors”). Macrophages activation leads to high sensory and
sympathetic innervation joint to angiogenesis in an arthritic
inflammation murine model.182 Macrophages, neutrophils, T-
lymphocytes, and mast cells express NGF.183,184 In damaged
nerves, macrophage-derived IL-1β induces the synthesis of NGF in
non-neuronal cells.175 There are no studies showing that
neurotrophins released by tumor-associated leukocytes contribute
to tumor innervation and neurogenesis in cancer, but it is
hypothetically possible.178,180
RECIPROCAL COMMUNICATION BETWEEN CANCER CELLS AND
THE NERVOUS SYSTEM PROMOTES TUMOR PROGRESSION
Nerves promote tumor growth, invasion, and metastasis; tumor-
associated-fibers are considered components of the tumor
stroma.47 Neuropeptides or neurotrophic factors released by tumor
cells promote axonogenesis to innervate the growing tumor185
(Fig. 3). In reciprocity, fiber-derived neurotransmitters as glutamate,
GABA (γ-aminobutyric acid), noradrenaline or acetylcholine stimu-
late tumor cell survival, proliferation, and migration. In addition,
neurotransmitters modulate pro- and anti-immune responses, also
affecting the tumor microenvironment by such indirect mechan-
isms. Therefore, potential therapeutic alternatives might be based
on stopping aberrant tumor neurogenesis and disrupting commu-
nication between cancer cells and neurons. Likely, combined with
conventional anti-tumor therapies, targeting neuromediator recep-
tors could be the basis of novel anti-neoplastic treatments in cases
where tumor-induced neurogenesis is proven to be relevant for
cancer progression.17
Peripheral nervous system in tumor axonogenesis and perineural
invasion
Tumor-derived neurotrophins as NGF and extracellular vesicles
can induce tumor innervation by stimulating branching of
adjacent nerve terminals, either of the somatosensory, motor, or
autonomic system,17,186 also contributing to cancer-associated
neuropathic pain.187 In pancreatic tumor xenografts (MIA PaCa-2
cells) chemical denervation (botulinum toxin) decreases the tumor
growth and increases apoptosis.188 In prostate cancer, nerve
density increases and correlates with cancer cell proliferation and
an increase in the expression of proteins involved in survival as
NFκB, c-Myc, GSK-2, PIM-2, SKP, SRF, PTEN, androgen receptor, and
estrogen receptor α.189 Invariably, patients with densely inner-
vated tumors will develop increased metastasis, have a poor
prognosis, and decreased survival.186,190
Cancer cells proliferate around peripheral nerves and eventually
invade them. This process, called perineural invasion (PNI), is a
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pathological feature of several types of cancer that correlates with
reduced survival of patients.25,191 This process could be a druggable
target as tumor-angiogenesis. Tumor cells migrate and expand
along nerves (Fig. 3), as an alternative route to metastasize. In vitro,
prostate tumor cells (PC3 cells) migrate along neurites branched
from the dorsal root ganglia (DRG). Adrenergic (β-blockers
propranolol and penbutolol) and muscarinic antagonists (atropine
and hyoscine) effectively inhibit prostate cancer cell migration along
neurites, suggesting that these nervous extensions provide
guidance and biophysical support to facilitate cancer cell dissemina-
tion, preventing this process could improve cancer therapeutics.
Sympathetic fiber-derived noradrenaline activates the β2-adrenergic
receptor and induces PNI via PKA/STAT3 activation. STAT3 leads to
the expression of NGF, MMP2, and MMP9 in pancreatic cancer cells
so that they can migrate and invade.192
Pancreatic ductal adenocarcinoma (PDAC) is exacerbated by
neuropsychological stress via β2-adrenergic signaling (PKA and
ERK pathways). In this case, tumor cells secrete NGF and BDNF
(brain-derived neurotrophic factor) stimulating nerve growth via
their Trk receptors (Tropomyosin-related kinase receptors) (Fig.
3). Therefore, β2-adrenergic antagonists (ICI-118, 551, proprano-
lol, but not atenolol) and inhibitors of Trk receptors (pan-Trk
inhibitor PLX-7486), potentiate the therapeutic effect of gemci-
tabine, prolonging mice survival, and non-selective β-blocker
treatment prolong survival of patients with PDAC.185 Interest-
ingly, hyperglycemia increases cancer cell proliferation and
induces NGF overexpression, promoting PNI in pancreatic
cancer. Furthermore, hyperglycemia-dependent demyelination
and axonal degeneration propitiate PNI.193 Finally, PNI induces
neuropathic pain during pancreatic cancer when tumor-derived
factors activate sensorial fibers to trigger pain; some of the
factors that increase in cancer cells are NGF, BDNF, artemin, and
glial cell-derived neurotrophic factor (GDNF), while their
receptors increase in nerves.187
Fig. 3 Axonogenesis is induced by oncogenic communication between cancer cells and adjacent sensorial/autonomic fibers. Tumor-derived
neurotrophins (as NGF and BDNF) promote the axonogenic switch of sensorial afferent and autonomic efferent fibers derived of tumor-
adjacent nerves. Then, nerve fibers innervating the tumors release factors allowing survival, proliferation, and migration of cancer cells. The
autonomic fibers innervating the tumor release noradrenaline and acetylcholine, providing a direct stimulus to receptors expressed in cancer
cells. Tumor-derived factors stimulate sensory fibers triggering pain, and the antidromic signals promote neuropeptides release (as SP) into
the tumor, activating NK1 in cancer cells and leading to growth factor receptor transactivation via Src (EGFR, HER2). The insert shows the
contribution of sympathetic and parasympathetic fibers during cancer progression. Sympathetic neurons contribute highly in early phases,
the sympathetic fiber-derived noradrenaline activates an angiogenic switch in endothelial cells, promoting neoplastic development. As the
contribution of sympathetic signaling decreases, there is a robust contribution of parasympathetic fibers in late phases inducing proliferation,
invasion, and metastasis
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Table 1. Endogenous molecules promoting tumor growth and potential co-adjuvant therapeutic targets as disruptors of oncogenic cell–cell
communication
Molecule and pro-tumor functions Type cancer (line/cell target) Genetic or pharmacological evidence, targets
Cancer cell stimulation
Noradrenaline/Adrenaline
α1D-adrenergic induced proliferation and
migration284
Prostate cancer cells (PC-3). α1D-adrenoceptor antagonist (A175).
β-adrenergic signaling induced by chronic stress
in cancer cells, β2-adrenergic signaling promotes
proliferation and survival230,231
Pancreatic ductal adenocarcinoma, acute
lymphoblastic leukemia, hepatocarcinoma.
β1 antagonist (Propranolol), β2 antagonist
(ICI118,551, butoxamine and propranolol)
improved sorafenib effect.
β2/3-adrenergic signaling promote angiogenic
switch by decreasing oxidative
phosphorylation190,226
Prostate cancer (PC-3). Chemical (6-OHDA) and surgical (hypogastric
nerve cut) sympathectomy; β2/3-adrenergic
knock out.
Acetylcholine (ACh)
Cholinergic fibers promote prostate cancer
invasion in late phases to metastasize via M1190
Prostate cancer cells (PC-3), ↑ stromal tumor. Muscarinic antagonist (scopolamine), M1
antagonist (pirenzepine). M1 receptor KO.
Parasympathetic neurogenesis is strongly
associated with tumor budding,233 particularly,
M3 receptor overexpressed234
Pancreatic ductal adenocarcinoma (PDAC). Unproven drugs for tumor budding.
Ionotropic acetylcholine receptor induces
proliferation and invasion236
Non-small-cell lung carcinoma. α5 nAChR antagonist (α-conotoxin and
mecamylamine), α7 nAChR antagonist (α-
bungarotoxin).
Substance P (SP)
NK1 receptor induces transactivation of EGFR
and HER in cancer cells220
Pancreatic cancer, breast cancer (MDA-MB-231
and MDA-MB-453), ↑vessels, ↑mast cells.
NK1 antagonist (L-733,060) synergizes with
HER2 inhibitors (AG825, AG1478, or lapatinib).
Glutamate (Glu)
mGluR1 overexpression drive melanoma through
PI3K/AKT/mTOR/HIF1 pathway265–267
Cutaneous melanoma. mGluR1 antagonist, inhibitor of glutamate
release (riluzole).
mGluR3 maintains glioma-initiating cells in an
undifferentiated state261
↑Chemotherapy-resistant glioma cells. mGlu3R antagonist (LY341495).
NMDAR induce cancer cell proliferation and
invasion271,272
Colon (HT29), astrocytoma (MOGGCCM),
breast (T47D), and lung (A549).
NMDAR antagonist (MK-801 or dizocilpine).
AMPAR induce cancer cell proliferation and
invasion272




Tumor cell proliferation by metabolizing GABA
and glutamate279
Breast cancer cell-brain metastasis (4T1). GABAT inhibitor (Vigabatrin), transporter
inhibitors, GAD67 inhibitors.
GABAB-R induces invasion and metastasis
mediated by ERK1/2280
Metastatic breast cancer. GABAB-R antagonist (CGP55845).
Dopamine (DA)
D2R induces cancer stem cells (CSC) survival254
Breast and lung cancer (↑CSC) D2R antagonist (trifluoperazine and
thioridazine).
Neurotrophins (NGF, BDNF)
In cancer cells, neurotrophins/Trk promotes
survival, proliferation, migration, and
invasion202,205,212–214
↑Ovarian cancer cells (OVCAR-3, SKOV-3,
OVCA420 / 429 / 433).
TrkB knockdown, pan-Trk inhibitor (PLX-7486).
Tumors with NTRK gene fusions. Trk inhibitor (larotrectinib/Vitrakvi, entrectinib/
Rozlytrek).
Neurotrophins strongly promote tumor-
angiogenesis205 BDNF recruits to EPC and pro-
angiogenic hematopoietic cells210
Gynecological cancers (↑endothelial cells).
↑EPC, ↑ Sca-1+CD11b+ cells.
TrkB inhibitor (K252a).
Immune evasion and pro-tumor BMDCs
PD-L1/PD-L2
Overexpression of PD-L1 in cancer, decrease of
IL-2 and IFN-γ production, reduced T cell
proliferation and cytotoxic effects83,87
Suppression of T-cell receptor (TCR) by SHP2
activation81




antibodies in cases of drug resistance to
cytotoxic chemotherapy.87 Anti-PD-1 synergize
with a vaccine against hepatocellular
carcinoma (GPC3-derived peptide)96
B7 (CD80)
Activates to CTLA-4 in cytotoxic T lymphocyte
and NK to suppress.108
Increase CD4+/FOXP3+ regulatory T cells100,123
Melanoma, head and neck sarcoma, colorectal
cancer, lung cancer, renal carcinoma,




EP receptors induce differentiation and
recruitment of MDSC22
Breast cancer (↑MDSCs) COX2 inhibitor (SC58236), EP1/2 antagonist
(AH6809), EP4 antagonist (AH23848).
IL-1β
Promotes the accumulation of MDSC in tumor285
Breast cancer (↑MDSCs). Physiological antagonist IL-1Ra, pathway
inhibitors.
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Table 1. continued
Molecule and pro-tumor functions Type cancer (line/cell target) Genetic or pharmacological evidence, targets
CCL2
Induce colonization of nerves by endoneurial
macrophages, relevant cells to perineural
invasion195
Prostate and pancreatic cancer (↑ endoneurial
macrophages).
CCR2 KO or KD. blocking anti-CCL2 antibody.
TGFβ
Decreases innate and adaptive antitumor
immune response134
Decrease NK cells135
Neuroblastoma and hepatocellular (↓NK). TGFβ-RI inhibitor (Galunisertib (LY2157299),
synergize with anti-GD2 (dinutuximab).
CD25
Increase Tregs phenotype133
Metastatic melanoma (↑Tregs CD25+ ). Anti-CD25 (Daclizumab) induces depletion of
Treg cells.
Dopamine (DA)
DA inhibits T cell proliferation and cytotoxic
capacity via D1 receptors247
Lung cancer D1/D5 antagonist (SCH23390).
Semaphorin 4D (Sema4D)
Sema4D+ macrophages increase tumor growth
by inducing angiogenesis and vessel maturation
by binding to the plexin B1 receptor on
endothelial cells172
Breast cancer murine model (TSA cells). Anti-plexin B1 c-Met inhibitor (PHA-665752).
Knock out sema4D
Catecholamines (NA/AD)
M2 macrophages polarization and induce VEGF
synthesis and secretion activating the angiogenic
switch160
Lung cancer (HCC827 and H446 cells). Chemical sympathectomy(6-OHDA);
β-antagonist (propranolol).
Tumor-derived factors
IL-10 and IL-4 cytokines of TME promotes
polarization of M2 macrophages previously
attracted by VEGF-A158,159
Breast cancer (↑M2 macrophages) VEGF-
induced skin carcinogenesis (HaCaT) (↑M2
macrophages).
Anti-IL10R antibody IL-4Ra-blocking antibody
Tumor axonogenesis/neurogenesis and perineural invasion
Noradrenaline/Acetylcholine
Cancer cell migration along neurites286
Prostate cancer cells (PC-3). β-antagonists (propranolol and penbutolol), M
antagonists (atropine and hyoscine).
Noradrenaline
β2-adrenergic induces perineural invasion via
PKA/STAT3 signaling in cancer cells192
Pancreatic cancer cells (MIA PaCa-2 and
BxPC-3).
β-antagonist (propranolol), PKA inhibitor
(KT5720), STAT3 inhibitor (AG490).
β-adrenergic signaling induces NGF and BDNF to
axonogenesis287
Pancreatic ductal adenocarcinoma. β2 antagonists (ICI-118,551, propranolol).
ACh
Parasympathetic signaling via M1 receptor in
tumor stroma promotes invasion and
metastasis190
Prostate cancer xenografts (PC-3). M1 receptor knock out. Nonselective M
antagonist (scopolamine), M1 antagonist
(pirenzepine).
TGFβ
Schwann cells releases TGF inducing
aggressiveness and perineural invasion200
Pancreatic cancer (Capan-2). TGFβ-RI inhibitor (SB-431542).
CCL2
Nerve-released CCL2 induces cancer cell
migration and PNI via CCR2 signaling194
Prostate cancer cell (PC-3, DU 145, and H292) CCR2 KO or KD. Blocking anti-CCL2 antibody.
CSF-1
Promotes recruitment of endoneurial
macrophages to the tumor-promoting perineural
invasion195
Melanoma, pancreatic cancer (↑M2
macrophages).
Anti-CSF-1R (emactuzumab in clinical trials).
CSF-1 receptor blocker (GW2580).
GDNF-GRFα1
Released by neurons, Schwann cells and
endoneurial macrophages to promote perineural
invasion195,197
Pancreatic adenocarcinoma. GFRα1 co-receptor knock down. RET inhibitors
(PYP1).
Semaphorin 4F (Sema4F)
Overexpressed in cancer cells, promotes
axonogenesis and potentially differentiation of
NPC242,243




G-CSF increases nerve outgrowth, invasion, and
metastases. Induces new parasympathetic and
sympathetic fibers244
Prostate tumor (PC-3). Unproven drugs.
In sensorial nerves, JAK/STAT3 signaling of
receptors G-CSFR and GM-CSFRα, promotes
cancer pain, CGRP release, and nerves’
sprouting222
Human pancreatic carcinoma Sarcoma (2472
fibrosarcoma cells)
anti-G-CSFR or anti-GM-CSFRα JAK inhibitor
(AG490).
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Tumor-associated nerves promote PNI because of CCL2
chemotactic actions. This chemokine is one of the most prominent
factors in the tumor-associated nerve secretome. CCL2 induces
cancer cell migration and PNI via CCR2 signaling.194 Moreover,
macrophages infiltrated into pancreatic adenocarcinomas con-
tribute to PNI. Nerve resident macrophages accumulate in the
nerves invaded by tumor cells by following the gradient of CCL2
and CSF-1 recognized by CCR2 and CSF-1R receptors, respectively;
CSF-1 receptor blocker (GW2580) prevents the migration of
endoneurial macrophages induced by tumor-derived factors.195
Then, tumor cell migration is triggered by RET receptors activated
by GDNF released by activated macrophages (Fig. 4). Cancer cell
migration induced by macrophage-derived GDNF depends on
GFRα1 co-receptor and RET, as demonstrated by the inhibitory
Table 1. continued
Molecule and pro-tumor functions Type cancer (line/cell target) Genetic or pharmacological evidence, targets
Neurotrophins (NGF, BDNF)
Induce tumor axonogenesis of autonomic and
sensorial fibers287
Pancreatic cancer (↑autonomic fibers, ↑NPC) Pan-Trk inhibitor (PLX-7486).
EphrinB1 exosomes
Cancer exosomes induce tumor innervation by
sensorial fibers186
EV-derived axonogenic signals are triggered by
loss of miR-34a225
Neck squamous cell carcinomas, colorectal
cancer (CT26 cells), melanoma (B16 cells),
breast cancer (4T1 cells) and cervical cancer
(Caski, HeLa, SiHa, and C66-3).
Rab27A/B knock out Neutral sphingomyelinase
inhibitor (GW4869 inhibits release of mature
exosomes).
Fiber-derived factors
Persistent pain (sensorial fibers) stimulate the
tumor growth46
Breast cancer (Walker 256 carcinoma cells). Anesthetic (bupivacaine), analgesic drug
(morphine).
Fig. 4 Tumor neurogenesis and perineural invasion, close and distant communication between cancer cells and neurons. In perineural
invasion, cancer cells migrate in response to different mediators released by autonomic and sensory fibers. Also, tumor cells secrete CCL2 and
CSF-1 to accumulate endoneurial macrophages and, at the same time, release factors that stimulate perineural invasion. Cancer stem cells
have the faculty to differentiate and acquire an autonomic neuron-like phenotype generating tumor-derived neurogenesis. Also, neurons and
Schwann cells release GRFα1 and GDNF (secreted by the endoneurial macrophages), activating RET in tumor cells. Besides, Schwann cells
release TGFβ, increasing the aggressiveness of cancer cells through TGFβ-RI. Schwann cells drive perineural invasion, cancer cells interact
directly with Schwann cells via NCAM1 to invade and migrate along nerves. Tumor-derived neurogenesis occurs when cancer stem cells
differentiate to neuron-like cells, particularly to autonomic neurons that release neurotransmitters to enrich the tumor microenvironment.
Tumor-induced neurogenesis is characterized by the recruitment of neural progenitor cells (NPC)-derived from the central nervous system
(CNS), particularly from the subventricular zone (SVZ). NPCs travel through the bloodstream attracted by tumor-derived factors, once they
infiltrate and colonize the tumor, they differentiate into functional autonomic neurons that stimulate tumor growth. DRG dorsal root ganglion,
SVZ subventricular zone, CNS central nervous system, NCAM1 neural cell adhesion molecule 1, ACh acetylcholine, NA noradrenaline, SDF-1
stromal derived factor, TH tyrosine hydroxylase, VAChT vesicular acetylcholine transporter, BDNF brain-derived neurotrophic factor, CCL2
chemokine (C–C motif ) ligand 2, CSC cancer stem cell, NPC neural progenitor cell
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effect observed in knock down experiments with cells lacking
GFRα1 co-receptor and the use of RET inhibitor (pyrazolopyrimi-
dine-1, PYP1). The signaling pathways controlling pancreatic
cancer cell migration involve MEK1 and AKT, as indicated by the
inhibitory effect of small molecules targeting these kinases.195
GFRα1 is a RET co-receptor that potentiates cancer cell migration
and enhances PNI. Interestingly, cancer cells that lack GFRα1 still
invade nerves because soluble GFRα1 and GDNF are released by
neurons and their associated Schwann cells,196 strongly activating
RET in cancer cells.197
Schwann cells drive PNI; cancer cells associate and use Schwann
cells to invade and migrate along nerves in pancreatic and thyroid
cancer (Fig. 4). In tumor nerves with PNI there is an increase in
Schwann cells (GFAP+, Glial fibrillary acidic protein) and they
intercalate with cancer cells by direct contact through NCAM1
(neural cell adhesion molecule 1). In NCAM1-deficient mice there
is a decrease in Schwann-cancer cell contact and the invasion
distance of nerves.198,199 Additionally, Schwann cells are a source
of TGFβ that activate SMAD signaling in pancreatic cancer cells
inducing migration, aggressiveness, and PNI, this effect is sensitive
to pharmacological inhibition of TGFβ-RI (SB-431542 inhibitor).200
Neurotrophins directly stimulate cancer cells and induce tumor
vascularization
Neurotrophins can directly induce tumor-axonogenesis (previous
section), cancer cells stimulation and tumor-angiogenesis; con-
necting the three processes that promote tumor growth. In oral
squamous cell carcinoma (OSCC), Trk receptors are overexpressed:
TrkA (for NGF), TrkB (for BDNF), and TrkC (for neurotrophin 3, NT3)
receptors. Cultures of highly metastatic cells (KON and HSC-3 cells)
and patient samples exhibited higher expression of TrkB and TrkC.
The presence of these receptors in OSCC patients correlated with
low disease-free survival,201 and in patients with ovarian cancer
high expression of TrkB correlated with low overall and disease-
free survival.202 However, in neuroblastoma patients, high
expression of TrkA or TrkC correlates with a better prognosis.203,204
In tumors, paracrine and autocrine neurotrophins directly
activate their receptors in cancer cells, activating PI3K/AKT, Ras/
ERK, and PLCγ/PKC signaling pathways for survival and prolifera-
tion (Fig. 3).204,205 Ovarian cancer cells (OVCAR-3, SKOV-3,
OVCA420, OVCA429, and OVCA433) overexpress TrkB, in fact,
HGF induces TrkB expression. BDNF/TrkB promotes ovarian cancer
cell migration and invasion and it is decreased in TrkB knockdown
cells while enhanced apoptosis.202 BDNF/TrkB inhibits the anoikis
in human ovarian cancer cells via PI3K/AKT, generating chemore-
sistant cells.206
The body distribution of blood vessels and nerve fibers is similar,
usually in a parallel manner. They share guiding molecules and
signaling mechanisms that promote the growth of axons and
blood vessels.207 This suggests that during cancer, the molecules
that promote angiogenesis could also induce axonogenesis/
neurogenesis mechanisms and vice versa. In fact, tumors are
innervated mainly by sympathetic fibers,208 this correlates with the
high parallelism of sympathetic nerves and body vasculature.
In gynecological cancers such as ovarian, cervical, uterine,
fallopian tubes, vulvar, vaginal, and gestational trophoblastic
neoplasms, neurotrophins strongly promote tumor-
angiogenesis.205 NGF and BDNF can promote angiogenesis
independently of VEGF (showed in Fig. 3); these factors could
explain the resistance of tumors to anti-VEGF therapy. In preclinical
models, BDNF promotes tumor growth by neovascularization, in a
murine tumor model produces large and hyper-vascularized
tumors (BNL cells in nude mice). BDNF overexpression in
endothelial cells increases proliferation and vascularization (sensi-
tive to the TrkB inhibitor K252a), while in patient samples with
hepatocellular carcinoma (HCC), BDNF and TrkB are overexpressed,
in fact, high expression of TrkB correlates with low patient
survival.209 BDNF has high angiogenic potential by recruiting
bone-marrow-derived cells as endothelial progenitor cells and pro-
angiogenic hematopoietic cells (Sca-1+CD11b+)210 and induces
differentiation of stem cells to endothelial cells.211 These effects
may be relevant in tumor angiogenesis and vasculogenesis.
Antagonism or inhibition of Trks could potentially prevent the
communication induced by neurotrophins, avoiding relevant
processes in cancer: neuroplasticity involved in neuropathic pain,
cancer cell proliferation, tumor-axonogenesis, and tumor-
angiogenesis. In 2018, the FDA approved an inhibitor of Trk
receptors, larotrectinib (Vitrakvi) for therapy of tumors with NTRK
gene fusions.212,213 While in 2019 was approved entrectinib
(Rozlytrek), a potent ATP-competitive inhibitor for Trks.205,214 It is
necessary to continue the research on the role of neurotrophins in
cancer and the effects of Trk inhibitors in conjunction with
conventional therapy.
Somato-sensorial nervous system: afferent fibers contribution to
cancer progression
Sensorial afferent neurons not only sense proprioception and
pain, but also modulate vascular and immune systems. In cancers
associated to the nervous system, tumor cells grow taking
advantage of sensory fibers which also enable cancer cells to
invade the peripheral and central nervous systems. Spinal
neuroinflammation detected by GFAP accompanies early stages
of pancreatic ductal adenocarcinoma. In these conditions, nervous
system damage is likely triggered by tumor-derived factors, and
then tumor cells invade sensory neurons and migrate towards
DRG and the spinal cord. Ablation of sensory neurons (C fibers
mainly) in a neonatal mouse model (induced by capsaicin)
prevents PNI and improves survival.215 Neuroinflammation trig-
gered by tumor-associated macrophages also contributes to
neuropathic pain.216
In tumors, there is communication among neurons, endothelial
and cancer cells. Afferent fibers-derived peptides as substance P,
commonly associated with inflammatory pain, are released on
demand after secretion of primary afferent terminals adjacent to
peripheral blood vessels by the antidromic depolarization.
Substance P activates Gq- and Gs-coupled receptors such as
NK1, promoting local endothelium-dependent vasodilation. In
cancer, this process propitiates tumor progression by enhancing
the availability of oxygen and nutrients. In addition, afferent
nervous terminals and mast cells induce local vasodilation and
inflammation through SP/calcitonin gene-related peptide (CGRP)
and histamine, respectively. Communication networks among
afferent fibers, mast cells and vessels exacerbate the tumor
microenvironment. Mast cells are activated by SP to release
vasodilators such as histamine that activate GPCRs in vascular
smooth muscle cells to promote vasodilation.217 Furthermore, in
murine melanoma models in which mast cells are sensitized with
IgE, this atopic status contributes to tumor growth. In mast cells,
the signaling pathways activated by the IgE/FcεRI/Fyn complex
induce VEGF synthesis and secretion, contributing to tumor-
induced angiogenesis218 (Fig. 2). GPCRs such as CB2 and GPR55
activated by anandamide and specific agonists inhibit mast cell
degranulation.219
Tumors are innervated by sensorial fibers, in papillary thyroid
cancer are detected peptidergic (sensorial fibers) and cholinergic
(parasympathetic fibers) innervations, although most nerves are
commonly adrenergic (sympathetic fibers).208 Direct communica-
tion between sensorial afferent fibers and cancer cells stimulates
proliferation and invasion of transformed cells. In breast cancer
cells, NK1 receptors, stimulated by SP, activate secretory pathways
that increase extracellular activity of metalloproteinases (MMPs);
turning on HER2 growth factor receptor transactivation which, via
Src, elicits proliferative and invasive processes.220,221 In fact, cancer
cells activate autocrine circuits by releasing SP, and in a preclinical
tumor model with breast cancer cells (MDA-MB-231 and MDA-MB-
453), NK1 antagonist (L-733,060) inhibits the tumor growth and
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synergizes with anti-HER2 therapies (AG825, AG1478 or lapatinib
inhibitors)176 (Fig. 3). These findings suggest that NK1 antagonists
could prevent growth factor receptor transactivation, restricting
proliferation, but also preventing the effect of SP on mast cells and
tumor peripheral vessels.
Hematopoietic growth factor receptors G-CSFR and GM-CSFRα
are expressed in sensorial nerves. Bone metastasis from pancreatic
carcinoma release granulocyte- and granulocyte-macrophage
colony-stimulating factors (G-CSF and GM-CSF), promoting cancer
pain. In sensory nerves, JAK/STAT3 signaling induces CGRP release
and sprouting nerves and hypertrophy. Antibodies against G-CSFR
or GM-CSFRα and JAK inhibitor (AG490) reduce tumor size, neurite
outgrowth, and cancer pain.222
Emerging research highlights the contribution of cancer-
derived exosomes to induce tumor axonogenesis, particularly by
innervation of sensorial fibers.186,223 Head and neck squamous cell
carcinomas (HNSCCs) are innervated by sensory nerves (TRPV1+,
Transient Receptor Potential Vanilloid-type 1), but not by
sympathetic (TH+, Tyrosine Hydroxylase) or parasympathetic
nerves (VIP+, Vasoactive Intestinal Polypeptide).186 Tumor released
exosomes containing EphrinB1 (EphB1, an axonal guidance
molecule) induce sensory innervation of the tumor (Fig. 3). EphB1
is a transmembrane protein that activates the Eph receptor
tyrosine kinases. Indeed, EphB1 knock out or the truncated
extracellular domain partially prevents exosome-dependent
axonogenesis.186
In murine models of human papillomavirus-induced head and
neck cancer, tumor innervation is attenuated by inhibiting
exosome release using Rab27A/B-deficient mEERL cells
(Rab27A−/+ Rab27B−/−) or pharmacological blockade of mature
exosome release by neutral sphingomyelinase inhibitor
(GW4869).186 In addition, exosomes from colorectal cancer
(CT26), melanoma (B16), and breast cancer (4T1) cells induce
neurite outgrowth (PC12, rat pheochromocytoma cell line).186
Tumor-derived exosomes promote sensory innervation observed
in human cervical cancer (TRPV1+ sensory nerves). Similarly,
cervical cancer cell lines (Caski, HeLa, SiHa, and C66-3) release
exosomes promoting neurite outgrowth (neuritogenesis).224
In oral cavity squamous cell carcinoma (OCSCC) high neural
density has been detected and correlates with poor survival. p53-
deficient cancer cells increase the tumor innervation by sensory
nerves.225 Loss of p53, either by knock out or p53 mutants
(p53R273H, p53C238F, and p53G245D) promotes the release of pro-
axonogenic extracellular vesicles increasing sensory nerves
infiltration. Conditioned media derived from human OCSCC cell
line (HN31 cells with p53C176F and p53A161S mutations) contain EV
and promote DRG neuritogenesis in vitro, while knock out of
GTPases Rab27A and 27B prevented the effect.225
EV-derived axonogenic signals are triggered by loss of miR-34a.
miRNA array of EVs derived from p53WT cells and p53null cells,
revealed the loss of miR-34a and miR-141. In fact, miR-34a knock
down or antagomiR-34a is enough to transform p53WT cell-
derived to p53KO cell-derived EVs, promoting neuritogenesis.225
Moreover, p53-deficient head and neck tumors are enriched with
adrenergic fibers and surgical lingual (sensorial) denervation
decreased tumor volume and intratumor adrenergic fibers. miR-
34a-deficient EVs regulates transdifferentiation of tumor sensory
nerves to adrenergic (sympathetic) nerves that promote tumor
growth.225 In human DRG or mouse TG sensory neurons, these EVs
induce biosynthesis and release of noradrenaline. EVs increase
sympathetic-associated genes expression and decreased sensory
neuron genes.225
Altogether, the data indicate that miR-34a-less EV drives a
sensory axonogenic switch and sensory nerve reprogramming to
the adrenergic nerve.225 In the TME, the joint effect of soluble
neurotrophic factors and pro-axonogenic EVs can lead to pro-
tumor innervation during cancer progression, establishing a new
pharmacologically modulable paradigm.223
Autonomous nervous system (NA and ACh): efferent fibers
contribution to cancer progression
In cancer patients, peripheral nerves that modulate autonomic
responses promote tumor growth. This effect is mediated by
infiltration of parasympathetic and sympathetic fibers within the
tumor stroma. Acetylcholine and noradrenaline secreted by nervous
terminals within the TME are recognized by their respective
receptors in cancer cells, stimulating tumor progression.190 Prostate
cancer studies have helped establish the participation of infiltrating
autonomic fibers in cancer progression. Sympathetic nerve activity
in the tumor is involved in early phases of the genesis of
neoplasia190 and for the angiogenic switch;226 while in later phases
the parasympathetic nerves promote invasion and metastasis (Fig. 3
insert).6,190 Another putative mechanism is linked to the immuno-
modulatory role of autonomic mediators which decrease anti-
tumor immune responses. Neuropathic pain suffered by cancer
patients is exacerbated by the aberrant communication between
autonomic and sensorial fibers; antidromic spontaneous shots of
sensorial fibers can enrich the TME. Autonomic fibers have a role in
allodynia during neuropathic pain, since they are able to
abnormally innervate to sensorial fibers, which propitiates their
spontaneous activation triggering pain227 (Fig. 4).
Sympathetic nervous system: noradrenaline and adrenaline as
pro-tumor mediators
Chronic stress promotes cancer growth. Noradrenaline, the main
neurotransmitter released by sympathetic fibers, plays a relevant
role in stress responses. Stress seems to be particularly relevant in
pancreatic cancer since pancreas is densely innervated by
sympathetic fibers.160,228 In pancreatic cancer orthotopic and
non-orthotopic murine models, bigger tumors are developed in
animals subjected to continuous stress. Moreover, anti-stress
pharmacological treatment attenuated pancreatic cancer progres-
sion.228 Pancreatic tumor growth is directly stimulated by
isoproterenol, a β-adrenergic receptor agonist, likely stimulating
β1 and β2 adrenergic receptors, both expressed in pancreatic
cancer cells. Consistent with the pro-oncogenic role of these Gs-
coupled receptors, constitutively-active Gαs mutant exacerbates
Ras-dependent pancreatic cancer.52 In addition, stress increases
MMP-2 and MMP-9 expression in tumor and stromal cells to
invade adjacent tissues. Very likely, direct β-adrenergic activation
of pancreatic stromal cells, as stellate cells, affects tumor growth.
Pancreatic stellate cells are like pancreas-specific fibroblasts that
contribute to inflammation and carcinogenesis.228 Also, in a model
of acute lymphoblastic leukemia, chronic stress increased cancer
cell dissemination via β-adrenergic signaling (sensitive to propra-
nolol). In this case, the effect seems to be mediated by the
response of cells from the bone marrow.229
Sympathetic innervation on endocrine organs inevitably con-
tributes to systemic effects of stress. Adrenal secretion of
adrenaline plays an evident role in cancer. Adrenaline stimulates
myeloma cell proliferation by activating β1- and β2-adrenocep-
tors, as indicated by the anti-proliferative effect of propranolol, a
β-blocker.230 In a model of chemically induced hepatocarcinogen-
esis, adrenaline promotes cancer cell proliferation and survival
triggered by β2-adrenergic signaling. It also inhibits autophagy
and promotes HIF-1α stabilization stimulating gene expression of
angiogenic factors. Adrenaline effect on tumor cells is inhibited by
β2 antagonists (ICI-118,551 and butoxamine) and by receptor
knockdown. Moreover, inhibition of β2-adrenergic signaling
improved sorafenib effects, a small molecule inhibitor that targets
VEGFRs, PDGFR, and RAF kinases.231
In OCSCC patients, p53-deficient tumors have high adrenergic
nerve density (TH+) and correlate with low recurrence-free survival
and lower overall survival rates. Sensory reprogramming to
adrenergic in p53-deficient tumors in mice treated with a non-
selective blocker of β1, β2, and α1 adrenergic receptors
(carvedilol) inhibits growth and proliferation.225
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Adrenergic signaling mediated by α1-adrenergic GPCRs also
exhibits pro-tumorigenic properties. According to preclinical
studies in cell cultures, pharmacological modulation (antagonists)
of these receptors decreases proliferation, migration, and adhe-
siveness of prostate cancer cells. The α1A-AR subtype is expressed
in androgen-sensitive prostate cancer cell lines (Rv1 and LNCaP
cells); in contrast, α1B and α1D subtypes are only expressed in
androgen-independent cancer cell lines (PC3 and DU145).
Experimental evidence shows that α1D-adrenoceptor induces
prostate cancer cell proliferation and migration.
In prostate cancer patients, high adrenergic nerve densities
correlate with low recurrence-free survival,190 hence the commu-
nication between nerves and endothelial cells could be an
interesting target for cancer therapies. Surprisingly, chemical (6-
hydroxydopamine, 6-OHDA) and surgical (hypogastric nerve cut)
sympathectomy inhibit the initiation of prostate tumors190 and
progression of lung cancer in murine models (HCC827 and H446
cells).160 Interestingly, β2/3 receptors are relevant in tumor stromal
cells, in mice lacking the β2 or β3 receptor, there is a delay in
tumor growth, while double KO shows an exacerbate phenotype,
arrest in tumor growth and angiogenesis.190,226 It has been
characterized that intratumor adrenergic nerves induce the
angiogenesis switch through endothelial stimulation by metabolic
adjustments in prostate cancer. The sympathetic fiber-derived
noradrenaline in the tumor activates β2-signaling in endothelial
cells and inhibits the expression of the mitochondrial cytochrome c
oxidase assembly factor COA6, consequently decreasing oxidative
phosphorylation and activating the angiogenic switch. Therefore,
inhibition of β2 adrenergic signaling in the tumor decreases
vascularization and tumor growth.226 Indirectly, sympathetic fibers-
derived noradrenaline promotes tumor neovascularization via
VEGF expression and secretion from polarized M2-macrophages.
This is prevented by chemical denervation and by the antagonist
propranolol thus inhibiting lung tumor growth in mice.160
The integration of the available information suggests that
axonogenesis and neurogenesis trigger angiogenesis induced by
adrenergic signaling. The suggested sequential processes are
pharmacologically adjustable. First, tumor-derived neurotrophins
induce axonogenesis of adjacent autonomic fibers and/or the
recruitment of neural progenitors, as described later in Section
“Tumor neurogenesis: CNS-derived neural progenitor cells
infiltrated in tumors”. Then, new intratumor sympathetic fibers
activate the angiogenic switch induced by noradrenaline and
neurotrophins on endothelial cells adjacent to tumor and pro-
angiogenic macrophages.
Parasympathetic nervous system: acetylcholine as a pro-
tumorigenic mediator
Parasympathetic neurogenesis is strongly associated with tumor
budding (presence of tumor cells isolated or in small groups
located in the infiltrating front of the tumor) in patients with
pancreatic ductal adenocarcinoma (PDAC). This process correlates
with poor prognosis as it correlates with cancer aggressiveness
and lower survival,232,233 particularly, high M3 receptor expression
correlates with poor prognostic and tumor budding.234 In prostate
cancer patients, high cholinergic nerve densities correlate with
low recurrence-free survival.190 Vesicular acetylcholine transporter
(VAChT) is the usual marker of parasympathetic neurogenesis and
it is usually quantified by immunostaining,235 and its hypothetical
pharmacological regulation could alter tumor growth.
Prostate tumors are infiltrated by parasympathetic cholinergic
fibers that promote cancer dissemination; in contrast to the early
contribution of sympathetic signaling, cholinergic signaling is
relevant in late stages for invasion and metastasis. Pharmacolo-
gical or genetic blockade of parasympathetic cholinergic signaling
(M1, muscarinic receptor) decreases the metastasis of prostate
cancer cells (Fig. 4).190 M1 receptor in tumor stroma promotes
aggressiveness of prostate cancer, carbachol (a muscarinic
agonist) enhances prostate cancer xenografts (PC-3) invasion of
lymph nodes and is prevented by nonselective muscarinic
(scopolamine) or M1 specific (pirenzepine) antagonists.190
Acetylcholine promotes proliferation and invasion of poorly
differentiated non-small-cell lung carcinoma as demonstrated by
the inhibitory effect of ionotropic acetylcholine receptor antago-
nists, particularly those that target heteropentameric α5 nAChR (α-
conotoxin and mecamylamine) or α7 nAChR homopentameric (α-
bungarotoxin) receptors.236 These nicotinic acetylcholine recep-
tors (nAChR) belong to the neuronal group of ionotropic receptors
activated by acetylcholine (5 α7 or, α2 α4 and 3 β2); which are
structurally related to muscle nicotinic (2 subunits α1, β1, δ, and γ)
receptors. All of them are ligand-dependent ion channels that
allow Na+ entry, leading to cell depolarization. Expression of
nicotinic receptors: α5, α7, β2, and β4 subunits, has been
identified in lung carcinoma tissue samples.
Tumor-derived neurogenesis: transdifferentiation of cancer stem
cells
Neuron-like cells have been observed in peripheral tumors. They
seem to be part of pathological mechanisms linked to the
differentiation of cancer stem cells (Fig. 4). In the case of gastric
and colorectal cancer, stem cells differentiate and acquire diverse
phenotypes, mainly of autonomic neurons expressing VAChT (a
marker of parasympathetic neurons), or TH (Tyrosine hydroxylase,
characteristic of sympathetic neurons). They also express MAP2
(MAP2, Microtubule Associated Protein 2), which is restricted to
cancer stem cells (CSC) with neural differentiation capacity within
the tumor. By knocking down MAP2 it has been revealed that these
undifferentiated cells generate functional autonomic neurons that
stimulate tumor growth. The knocking down of MAP2 decreased
the generation of neurons from human gastric and colorectal
cancer stem cells and reduced the growth of tumor xenografts
derived from human colorectal cancer stem cells.235 Similarly, as
characterized in glioblastoma, tumor stem cells differentiate to
endothelial-like cells forming vessels that irrigate tumors.237,238
Destroying cancer stem cells, as well as pharmacological inhibition
of cancer stem cell differentiation, could prevent cancer progres-
sion. In order to design specific drugs suitable to inhibit aberrant
cell differentiation into tumor-accelerating phenotypes, similar to
neurons or endothelial cells, it is important to identify factors and
conditions that lead cancer stem cell transdifferentiation, so they
could be regulated with therapeutic goals in mind.
Tumor neurogenesis: CNS-derived neural progenitor cells
infiltrated in tumors
Tumor-induced neurogenesis occurs in prostate cancer through
neural progenitor cell migration and differentiation of neurons
into tumors (Fig. 4). The central nervous system (CNS)-derived
neural progenitor cells (NPC) are recruited by prostate cancer cells
to the primary tumor and metastasize in early stages, where
initiate neurogenesis, generating adrenergic neurons mainly.239
This is consistent with the sympathetic contribution in early
phases demonstrated in prostate cancer.190 Neural progenitor
cells (marker doublecortin+, a microtubule-associated protein)
from neurogenic regions of the brain (subventricular zone, SVZ)
cross the blood–brain barrier and travel by the bloodstream until
they infiltrate the tumors where they differentiate.239
The study of tumor neurogenesis in gastrointestinal malignan-
cies is necessary, considering that enteric neural progenitor cells
are more efficient in generating neurons (e.g. colon) than brain-
derived progenitor cells.240 While in glioblastoma, brain tumor
stem cells produce tumor neurogenesis, but also have tumor
initiation capacity. The migration of both cells requires PI3K/AKT
and Cdc42 activation and the inhibition of small GTPases, and PI3K
prevents the migration and invasive capacity.241 CXCL12/
CXCR4 signaling is relevant to NPC migration, and probably
participates in tumor recruitment. In the opposite direction,
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glioblastoma stem cells invade SVZ through CXCL12/CXCR4; the
tropism induced by CXCR4 activation can be avoided using
antagonists (AMD3100 and PRX177561).241
Altogether axonogenesis and neurogenesis increase nerve
density around the tumor and the number of dorsal root ganglion
neurons in human prostate cancer242 and pancreatic cancer tissue
compared to normal tissue.188 Prostate cancer cells overexpress
semaphorin 4F (Sema4F) and its knock down inhibits the tumor
axonogenesis and neurogenesis in vitro.242 Additionally, over-
expression of Sema4F induces proliferation and migration of
prostate cancer cells (DU145) and correlates with a recurrence-free
survival of patients with prostate cancer.243 Sema4F may
contribute to the communication between fibers and cancer cells
for this to ultimately migrate along fibers.
Granulocyte colony-stimulating factor (G-CSF) has neurotropic
functions; in prostate tumor mice (Hi-Myc) G-CSF increased nerve
outgrowth, invasion, and metastases. G-CSF induces new choli-
nergic parasympathetic nerve fibers in the orthotopic tumor for
metastasized. Interestingly, G-CSF administration rescued the
development of orthotopic tumor xenografts previously sym-
pathectomized with 6-OHDA, protected sympathetic neurons.244
G-CSF may promote the recruitment of neural progenitor cells to
increase sympathetic cells in the tumor. The tumor-derived factors
that particularly promote the migration of neural progenitor cells
are unknown, and it is necessary to deepen into the characteriza-
tion of tumor mediators that induce the migration and
differentiation of NPCs to develop small molecules that inhibit
the tumor neurogenesis process. Neurotrophins17 and extracel-
lular vesicles225 enriched in the tumor possibly promote the
differentiation of neural progenitor cells to tumor-associated
sensory and autonomic fibers. Tumor axonogenesis and neuro-
genesis are potential targets for cancer therapy.
CLASSICAL CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS
(DOPAMINE, GLUTAMATE, AND GABA) IMPACT CANCER
PROGRESSION
Systemic dopamine in tumor progression
Dopamine (DA), a monoamine neurotransmitter characteristic of
the CNS, affects the interplay between the immune and central
nervous systems. Therefore, immune responses controlled by DA
mediate the effects of this neurotransmitter in cancer progression.
Immune cells, including B lymphocytes, NK cells, monocytes,
macrophages, dendritic cells, neutrophils, effector and regulatory
T cells express dopamine receptors,245 which are either coupled to
Gs (D1R and D5R) or Gi (D2R, D3R, and D4R). Dopamine is
produced not only by the brain, but also by peripheral organs
including the digestive tract, spleen, and pancreas.246 Peripheral
dopamine modulates anticancer immune responses. In patients
with lung cancer, dopamine plasma levels increase up to 5-fold,
reaching immunomodulatory concentrations that, in vitro, inhibit
T cell proliferation and cytotoxic capacity. This effect, demon-
strated in samples from normal donors and cancer patients, occurs
via D1 receptors, sensitive to SCH23390 (D1R/D5R antagonist).247
Some cancer cells are directly affected by DA. For instance,
dopamine inhibits osteosarcoma cell proliferation via down-
regulation of ERK1/2 and PI3K/AKT pathways, controlled by D1
receptors.248 In the case of gastric cancer cells, DA inhibits
migration and invasion, potentially via inhibition of the EGFR-AKT
pathway.249 In gastric cancer, increased expression of D2R
negatively correlates with patient survival.250 Similarly, increased
levels of D2R have been detected in samples of cervical,251
lung,252 and breast cancer.253 In preclinical cancer models,
dopamine receptors are being studied as potential drug targets.
In murine lung cancer, D2R agonist inhibits angiogenesis, limiting
tumor advance, although the mechanism remains to be clar-
ified.252 This suggests that D2R agonists may be useful adjuvants
in anti-tumor conventional therapy to lung carcinoma.254
Paradoxically, D2R antagonists as trifluoperazine and thioridazine
eradicate cancer stem cells (CSC) in breast and lung cancer, cells
that resist and survive conventional therapy.255 Given the
contribution of cancer stem cells (CD133+) to carcinoma progres-
sion, the finding that they overexpress D2R raises interesting
opportunities for pharmacological intervention. Control of this
system in cancer stem cells reduces proliferation and invasiveness
by suppression of ERK and AKT pathways and down-regulation of
MMP9 and octamer-binding transcription factor 4 (Oct-4).254
These effects on cancer stem cells support the possible use of
antipsychotic drugs as co-adjuvants to existing therapy.255
Although further evidence is required to assure the role of
dopamine receptors against CSC survival, this offers a new
promise for cancer treatment. In addition, other dopamine
receptors might be relevant targets. Accumulating evidence
includes D4R, which has also been found overexpressed in breast
cancer, and D5R which, according to preclinical studies, promotes
autophagy leading to cell death via increased ROS production and
inhibition of the mTOR pathway.256
Glutamate metabotropic and ionotropic receptors in cancer
Glutamate (Glu), a paradigmatic excitatory neurotransmitter in the
mammalian brain, is tightly controlled to prevent neuronal death
due to excitotoxicity. Altered glutamatergic signaling has been
linked to several neurodegenerative diseases and disorders, as well
as oncogenic and metastatic processes in glioma (the most
common type of primary brain tumors), such as glioblastoma, the
most frequent and lethal cancer of the central nervous system;257
among other cancer types.258 Increased glutamate levels occur in
glioma and astrocytomas (Fig. 5a). In vitro, malignant cells release
enough glutamate to reach neurotoxic concentrations. Moreover,
aberrant glutamatergic signaling in glioma has also been linked to
decreased glutamate uptake due to poor glutamate transporter
activity (EAAT, excitatory aminoacid transporter), or expression
(GLT1, glutamate transporter-1 and GLAST, glutamate/aspartate
transporter).258,259
Although high levels of extracellular glutamate are toxic for
normal neurons; this neurotransmitter has neurotrophic effects in
GBM.257 Glutamate is the natural agonist of ionotropic (iGluRs,
which are ion channels) and metabotropic (mGluRs, G protein-
coupled) receptors. The first group includes: N-methyl-D-aspartate
receptors (NMDAR), a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid receptors (AMPAR), and kainate receptors (KAR); the
second is composed by eight G protein-coupled receptors
(mGluR1, R2, R3, and R5 are Gq protein-coupled; while mGluR4,
R6, R7, and R8 are coupled to heterotrimeric Gi proteins).260 In
chemotherapy-resistant glioma cells, mGluR is considered an
oncogene. In vitro, a mGlu3R agonist (LY379268, mGluR2/3
agonist) maintains glioma-initiating cells in the undifferentiated
state, whereas a mGlu3R antagonist (LY341495) induces differ-
entiation to astrocytes. In vivo mGlu3R antagonists limited brain
tumor growth or infiltration in nude mice models.261
In non-neuronal cancer cells, genomic and proteomic studies
have revealed glutamate receptor mutations and aberrant gluta-
matergic signaling related to iGluRs, mGluRs, and their downstream
effectors.258,262 Known to be absent in normal melanocytes,263,264
mGluR1 was detected in 7 out of 19 biopsies from melanoma
patients, and in 12 out of 18 melanoma cell lines.264 These findings
suggested a potential role for mGluR1 in melanoma progression. In
mouse models, stable melanocyte expression of mGluR1 is
sufficient to transform cells, enabling aggressive tumorigenic
properties.263–265 Overexpression of mGluR1 generates larger and
aggressive murine melanoma tumors with increased blood vessels.
Mechanistically, mGluR1-dependent activation of the PI3K/AKT/
mTOR/HIF1 pathway increased the content of IL-8 and VEGF in the
tumor microenvironment, promoting proliferation, survival and
angiogenesis266 (Fig. 5a). In this model, an inhibitor of glutamate
release (riluzole), prevented tumor growth. Riluzole is being
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assessed, with promising results, in advanced melanoma patients
included in phase II clinical trials.267 Reminiscent of uveal melanoma
driven by mutant Gq/11,51 which in preclinical studies is sensitive to
FR900359,268 the mGluR1/Gq signaling pathway emerges as a
potential target in melanoma.
NMDAR has been detected in different tumors.269 Specifically, the
NR2B subunit is increased in biopsies from glioma, pancreatic
ductal carcinoma, breast and ovarian cancer.270 Accordingly,
different human cancer cell lines exhibit NMDAR functionality. A
paradoxical role of NMDAR in cancer has been revealed by the anti-
tumor effects of both agonists as well as antagonists. These
intriguing observations are likely linked to different signaling
pathways being effective in different cancer types.271 In fact,
NMDAR antagonist (MK-801 or dizocilpine) and AMPA antagonist
(GYKI52466) inhibit cancer cell proliferation and invasion, whereas
they are innocuous in human skin fibroblasts and bone marrow
stromal cells271,272 Dizocilpine was effective against colon adeno-
carcinoma (HT29), astrocytoma (MOGGCCM), breast carcinoma
(T47D), and lung carcinoma (A549), whereas AMPA antagonist
(GYKI52466) was effective in breast carcinoma (T47D), lung
carcinoma (A549), colon adenocarcinoma (HT29), and neuroblas-
toma (SKNAS). Indicative of their potential in combined therapies,
glutamate antagonists improve the effect of cytostatic drugs.272
NMDAR behaves as a tumor suppressor as its agonists inhibit
cancer cell proliferation by interfering with mTOR and ERK signaling
pathways.271 Accordingly, multiple cancer cell lines including gastric
cancer lines,273 human esophageal cancer274 and non-small-cell
lung cancer cell lines275 show decreased expression of NMDAR2B
subunit. In fact, epigenetic control of the NR2B subunit promoter,
by methylation, is being postulated as a biomarker in gastric cancer.
In these cancers, NMDA suppresses disease progression. NMDAR
activation triggers the internalization of CAT 1 and 3 (cationic amino
acid transporters). Therefore, in response to low levels of
intracellular arginine, AMPK inhibits mTORC1.276 Also, NMDA-
dependent increase of cytosolic calcium activates calcineurin which
in turn activates STEP (striatal enriched protein tyrosine phospha-
tase), inhibiting ERK1/2277 as part of the anti-mitogenic mechanism.
Given the antiproliferative effects of NMDAR agonists, clinical trials
and precise patient selection likely will validate the therapeutic
potential of these emerging antineoplastic agents.
GABAergic system modulates breast cancer metastasis and
prostate cancer
GABA (γ-aminobutyric acid), an inhibitory neurotransmitter that
activates agonist-gated ionotropic channels (GABAA-R, allowing
Cl− efflux), and Gi-protein coupled receptors (GABAB-R), is widely
distributed in the CNS and other peripheral tissues. Given the high
prevalence of cancer metastasis to the brain, GABA (as other
neurotransmitters), has been studied as a potential oncometabo-
lite helping to establish metastatic niches in the brain.278
In the case of breast cancer patients, the brain is commonly
colonized by tumor cells. Interestingly, perhaps as an adaptability
mechanism, metastatic breast cancer cells invading the brain
express GABAA-R and a repertoire of related proteins similar to
those of GABAergic neurons, including GABA transaminase
(GABAT), glutamate decarboxylase (GAD67), GABA transporter,
reelin, and parvalbumin.279 The 15 isoforms of the GABA receptor
mRNA, as well as vesicular GABA transporter (VGAT), GABA 1 to 3
transporter (GAT1-3) and the betaine-GABA transporter (BGT)
expression are highly regulated in HER2+ breast cancer brain
metastases. Therefore, metastatic tumor cells acquire GABAergic
machinery enabling them to survive and proliferate in response to
GABA. These acquired abilities are independent of GABAA receptor
signaling, as indicated by the proliferative effect of GABA even in
the presence of muscimol, a GABAA antagonist. GABA-induced
proliferation of metastatic tumor cells is attributed to their gained
ability to uptake and catabolizes GABA, producing succinate and
NADH as a biosynthetic source (Fig. 5b). Consistent with this
possibility, the proliferative effect of GABA on metastatic cells is
abolished by vigabatrin (GABA transaminase inhibitor). In addition,
some metastatic tumor cells in the brain overexpress GAD67, an
enzyme that converts glutamate to GABA, sustaining an additional
metabolic source to promote cancer proliferation in the brain.279
Therefore, GABA transaminase and other proteins linked to the
acquired ability of metastatic cells in the brain to feed on GABA
and glutamate, as sources of biosynthetic energy, emerge as
potential therapeutic targets to treat metastatic breast cancer.
Out of the central nervous system, GABA plays a role in cancer.
For instance, GABAB receptors enhance the aggressive behavior of
metastatic breast cancer cells invading the lungs. A mice model of
breast cancer showed that a GABAB-R agonist potentiates lung
Fig. 5 Glutamate, GABA, and dopamine contribution to cancer progression. a Glutamate stimulates tumor cell proliferation and survival via
metabotropic (mGluR3, mGluR1) and ionotropic (NMDAR and AMPAR) receptors; particularly, mGluR1 overexpression drives melanoma. Direct
effects of dopamine and GABA on cancer cells promote survival and proliferation via D1/5 and GABAB receptors, respectively. Glutamate
release is increased in glioma cells. Dopamine induces survival and proliferation of cancer stem cells (CSC) via D2 receptor, anti-psychotic
drugs decrease the CSC population. b Metastatic brain cells from breast cancer acquire GABAergic properties to take advantage of GABA and
glutamate neurotransmitters sustaining their metabolism and survival. GABA and glutamate are uptaken by GAT and EAAT2, respectively, in
metastatic cells; the neurotransmitters are metabolized. In addition, GABA receptor activation in cancer cells promotes metastasis. Blockers for
GABA (GAT) and glutamate (EAAT2) transporters and GABA antagonist could inhibit the survival and proliferation of metastatic cancer cells
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metastasis without affecting primary tumor volume, whereas an
antagonist decreased metastases.280 Baclofen, a GABAB-R agonist,
induces migration, invasion, and metastasis mediated by ERK1/2; in
contrast, a GABAB-R antagonist (CGP55845) decreased migration
and invasion. GABA is a neurotrophic factor effective during neural
crest development and exhibits similar effects in neural crest-
derived chondrosarcoma. In a human chondrosarcoma cell line,
GABA promotes proliferation; in contrast, a GABAB-R antagonist
(CGP54626) induced apoptosis by inhibition of the PI3K/AKT/mTOR
and MAPK pathways and activation of caspases 3 and 9.281 These
results encourage the characterization of GABAB drugs as potential
co-adjuvants of current chondrosarcoma therapy.
In prostate cancer282,283 GABAA-R is expressed in cancerous
gland tissue, but absent normal tissue. Thus, this chlorine channel
brings about the GABAergic system to aggravate the situation in
prostate cancer. Consistent with this role, GABA and isoguvacine
(GABAA-R agonist) increased prostate cancer (PCa) cell prolifera-
tion, particularly in the case of two cell lines: PC-3 cells (bone
metastasis, androgen-independent) and LNCaP (lymph node
metastasis androgen-dependent). The proliferative mechanism
activated by GABAA-R in prostate cancer cell lines is likely
mediated by transactivation of EGFR and Src-dependent prolifera-
tion.282 In fact, 3α-diol neurosteroid, synthetized from 5α-
dihydrotestosterone by AKR1C3 (Aldo-keto reductase family 1
member C3), induces PC-3 cell proliferation and promoted growth
of large vascularized tumors in a GABAA-R-dependent manner. 3α-
diol is an allosteric modulator of GABAA-R, increasing EGF
expression and subsequent activation of EGFR, leading to an
increase in cell proliferation. These effects are prevented by
GABAA-R antagonists (dihydroergotoxine mesylate, picrotoxin, or
bicuculline methobromide picrotoxin). Therefore, inhibition of
AKR1C3 and GABAA-R in prostate cancer would hypothetically
potentiate conventional therapy.283
CONCLUSIONS
Conventional antineoplastic therapies lack specificity and their high
toxicity limits their efficacy. Ideally, they should be combined with
more precise therapeutic molecules obtained by knowledge-based
design. Therefore, current efforts aimed to achieve a deep under-
standing of the mechanistic basis of cancer pathophysiology are
revealing novel therapeutic targets (Table 1). Cell communication is
the focus of innovative therapies. Angiogenesis inhibitors have
proven the concept; although they are effective in a limited number
of cancer patients and resistance is an emerging problem. To face
this challenge, it is important to continue evaluating cell commu-
nication in cancer, keeping in mind the complexity of the tumor
microenvironment and the contribution of multiple cells and
systems. In this review, some oncogenic communication networks
among cancer cells, leukocytes, and neurons were discussed (Fig. 6),
pointing out emerging targets, particularly receptors within the
neuro-immune system (visualized from an integral perspective).
These knowledge-based targets are essential players in the commu-
nication among different cells and systems, known to sustain cancer
progression. The goal is to target them as co-adjuvants in cancer
therapy to counteract those mechanisms by which cancer cells evade
the immune system and those that promote axonogenesis,
neurogenesis and PNI. New anti-neurogenic drugs and immu-
notherapies are an opportunity against cancer. In conclusion, as a
paramount player in cancer progression, the neuro-immune axis is an
important source of communication molecules and their receptors
are being characterized as therapeutic targets that will revolutionize
the efficacy and potency of conventional chemotherapies.
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